Yatin Suneja
Stock Analyst at Guggenheim
(3.34)
# 899
Out of 4,944 analysts
133
Total ratings
47.11%
Success rate
2.57%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $810 → $815 | $561.55 | +45.13% | 7 | Aug 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $165 → $175 | $131.62 | +32.96% | 6 | Aug 1, 2025 | |
| ARGX argenx SE | Maintains: Buy | $1,060 → $1,070 | $646.60 | +65.48% | 12 | Aug 1, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Buy | $50 → $101 | $69.89 | +44.51% | 2 | Jul 23, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Buy | $26 | $3.72 | +598.92% | 6 | Jun 25, 2025 | |
| ALMS Alumis | Reinstates: Buy | $18 | $4.42 | +307.24% | 2 | Jun 10, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $54 → $90 | $20.74 | +334.05% | 13 | May 28, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $23 → $25 | $1.71 | +1,361.99% | 5 | May 16, 2025 | |
| GHRS GH Research | Maintains: Buy | $32 → $29 | $12.56 | +130.89% | 1 | May 9, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $18 → $12 | $10.48 | +14.50% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.59 | +843.40% | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $0.82 | +1,125.49% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.69 | +920.41% | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $15.89 | - | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $20.86 | +302.78% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $16.75 | +168.66% | 3 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.56 | - | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $45 | $10.06 | +347.32% | 3 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $25.13 | -20.41% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.81 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $22.22 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $65 | $17.40 | +273.56% | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $155 → $170 | $49.05 | +246.59% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.60 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $24.99 | +260.14% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $109.39 | +14.27% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $11.96 | +33.78% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $55.65 | +38.36% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.60 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $37.67 | +30.08% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $11.01 | +399.55% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $135.19 | +158.89% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.57 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $14.17 | +69.37% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $105.20 | -67.68% | 2 | Jan 14, 2020 |
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Buy
Price Target: $810 → $815
Current: $561.55
Upside: +45.13%
Neurocrine Biosciences
Aug 1, 2025
Maintains: Buy
Price Target: $165 → $175
Current: $131.62
Upside: +32.96%
argenx SE
Aug 1, 2025
Maintains: Buy
Price Target: $1,060 → $1,070
Current: $646.60
Upside: +65.48%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Buy
Price Target: $50 → $101
Current: $69.89
Upside: +44.51%
Larimar Therapeutics
Jun 25, 2025
Reiterates: Buy
Price Target: $26
Current: $3.72
Upside: +598.92%
Alumis
Jun 10, 2025
Reinstates: Buy
Price Target: $18
Current: $4.42
Upside: +307.24%
AnaptysBio
May 28, 2025
Maintains: Buy
Price Target: $54 → $90
Current: $20.74
Upside: +334.05%
Cabaletta Bio
May 16, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $1.71
Upside: +1,361.99%
GH Research
May 9, 2025
Maintains: Buy
Price Target: $32 → $29
Current: $12.56
Upside: +130.89%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $18 → $12
Current: $10.48
Upside: +14.50%
Mar 26, 2025
Reiterates: Buy
Price Target: $15
Current: $1.59
Upside: +843.40%
Mar 26, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $0.82
Upside: +1,125.49%
Mar 21, 2025
Reiterates: Buy
Price Target: $7
Current: $0.69
Upside: +920.41%
Mar 20, 2025
Reiterates: Buy
Price Target: n/a
Current: $15.89
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $84
Current: $20.86
Upside: +302.78%
Mar 12, 2025
Reiterates: Buy
Price Target: $45
Current: $16.75
Upside: +168.66%
Mar 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.56
Upside: -
Jan 3, 2025
Upgrades: Buy
Price Target: $45
Current: $10.06
Upside: +347.32%
Jan 3, 2025
Downgrades: Neutral
Price Target: $20
Current: $25.13
Upside: -20.41%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.81
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $22.22
Upside: -
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $17.40
Upside: +273.56%
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $49.05
Upside: +246.59%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.60
Upside: -
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $24.99
Upside: +260.14%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $109.39
Upside: +14.27%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $11.96
Upside: +33.78%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $55.65
Upside: +38.36%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $5.60
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $37.67
Upside: +30.08%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $11.01
Upside: +399.55%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $135.19
Upside: +158.89%
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.57
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $14.17
Upside: +69.37%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $105.20
Upside: -67.68%